Last Updated on October 15, 2024 by The Health Master
CTI BioPharma Corp said on Monday the U.S. Food and Drug Administration (USFDA) had approved its drug for treating adult patients with a type of bone marrow cancer who also have low blood platelet count.
The drug, Vonjo (pacritinib), belongs to a class of anti-inflammatory treatments called JAK inhibitors, and will compete with Incyte Corp’s Jakafi and Bristol Myers’ Inrebic, which were approved in 2011 and 2019 respectively for treating Myelofibrosis.
Myelofibrosis causes extensive scarring in the bone marrow and disrupts the body’s production of blood cells, causing low platelet count, anemia, weakness, fatigue and often swelling of the liver and spleen.
Incyte expects to generate revenue of $2.3 billion-$2.4 billion in U.S. sales alone, while Inrebic, which was acquired by Bristol after it bought Celgene in 2019, generated about $74 million in sales last year.
“We currently model that the company could get 30% market share, leading to revenue of approximately $390 million,” said JMP Securities analyst Benjamin Reni.
Reni expects CTI BioPharma to charge an annual price of $260,000 per year for the treatment, a significant premium to Jakafi’s price of $187,000 per year and a discount to Inrebic’s $275,184 per year.
CTI BioPharma Chief Executive Officer Adam R. Craig said, “We are fully funded for commercial launch, following our debt and royalty transactions with DRI, and we look forward to providing VONJO to patients within 10 days.”
The company said the drug was approved under priority and the nod triggered $60 million payment from DRI Healthcare Trust.
In a late-stage study in patients with severe thrombocytopenia who were treated with CTI BioPharma’s drug twice a day, 29% of patients had a reduction in spleen volume, compared to 3% of patients receiving the best available therapy, which included Jakafi.
In November, the U.S. health regulator had delayed its decision for the drug by three months to review additional data previously submitted by the company.
USFDA gives nod to Unichem Laboratories for Divalproex Sodium
USFDA approves this drug for all heart patients to cut death, hospitalization risk
USFDA gives nod to Zydus to market Dapagliflozin tablets
USFDA gives nod to Strides Pharma for Amantadine HCL Softgel Capsules
USFDA gives nod to Lupin for sNDA for Solosec
USFDA gives nod to this Molecule to treat retinal vascular diseases
NDPS Exporters and Importers to register with ICEGATE portal: CBN
USFDA gives nod to Unichem Laboratories for Divalproex Sodium
20 projects worth Rs. 840 crore for PLI scheme for Bulk drugs
Drug recall: Aurobindo, Sun Pharma recall these products
CDSCO gives nod to Sun Pharma to conduct Phase 4 clinical…
Drug recall: Medical Device – Infusion Pumps recalled due to this reason
How Antibiotics polluting Indian rivers: Study
Now, focus on e-consultation: Govt
Clinical trial of plant based drug for fatty liver soon: CDRI
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
